Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$8.85
-3.5%
$9.11
$0.06
$14.93
$6.76M0.98566,370 shs3,647 shs
CEL-SCI Co. stock logo
CVM
CEL-SCI
$2.49
-1.2%
$4.17
$1.98
$66.60
$7.55M0.379,414 shs192,158 shs
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
$0.13
-21.8%
$0.12
$0.10
$2.15
$6.92M1.653.56 million shs4.81 million shs
TradeUP Acquisition Corp. stock logo
UPTD
TradeUP Acquisition
$0.88
-0.1%
$1.51
$6.88
$33.00
$1.91M0.12270,115 shs16,938 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.00%-0.78%-3.17%-3.17%-76.59%
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.00%+3.75%+4.62%-60.21%-93.14%
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
0.00%0.00%0.00%0.00%-92.98%
TradeUP Acquisition Corp. stock logo
UPTD
TradeUP Acquisition
0.00%-0.11%-16.98%0.00%-27.27%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
1.6553 of 5 stars
3.50.00.00.03.00.00.0
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.0741 of 5 stars
0.02.00.00.00.00.00.6
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
2.1151 of 5 stars
3.40.00.00.00.61.71.3
TradeUP Acquisition Corp. stock logo
UPTD
TradeUP Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
3.00
Buy$275.003,007.34% Upside
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.00
N/AN/AN/A
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
2.80
Moderate Buy$8.506,700.00% Upside
TradeUP Acquisition Corp. stock logo
UPTD
TradeUP Acquisition
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$146K46.31N/AN/A$0.20 per share44.25
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/A$0.15 per shareN/A
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
$8.10M0.85N/AN/A$1.05 per share0.12
TradeUP Acquisition Corp. stock logo
UPTD
TradeUP Acquisition
N/AN/AN/AN/A($1.59) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
-$28.96M-$24.00N/AN/AN/A-12,594.21%-421.73%-147.54%N/A
CEL-SCI Co. stock logo
CVM
CEL-SCI
-$26.92M-$12.61N/AN/AN/AN/A-238.05%-104.65%N/A
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
-$97.43M-$1.33N/AN/AN/A-902.93%-213.13%-41.24%N/A
TradeUP Acquisition Corp. stock logo
UPTD
TradeUP Acquisition
-$1MN/A0.00N/AN/AN/A-3.38%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
N/AN/AN/AN/AN/A
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/AN/A
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
N/AN/AN/AN/AN/A
TradeUP Acquisition Corp. stock logo
UPTD
TradeUP Acquisition
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.05
0.75
0.75
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.66
1.07
1.09
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
1.00
1.61
1.61
TradeUP Acquisition Corp. stock logo
UPTD
TradeUP Acquisition
N/A
0.09
0.09

Institutional Ownership

CompanyInstitutional Ownership
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
12.02%
CEL-SCI Co. stock logo
CVM
CEL-SCI
12.08%
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
97.47%
TradeUP Acquisition Corp. stock logo
UPTD
TradeUP Acquisition
34.95%

Insider Ownership

CompanyInsider Ownership
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.02%
CEL-SCI Co. stock logo
CVM
CEL-SCI
9.93%
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
8.50%
TradeUP Acquisition Corp. stock logo
UPTD
TradeUP Acquisition
55.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
20764,00068.74 millionNot Optionable
CEL-SCI Co. stock logo
CVM
CEL-SCI
433.03 million64.67 millionOptionable
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
12055.37 million50.66 millionOptionable
TradeUP Acquisition Corp. stock logo
UPTD
TradeUP Acquisition
2,0212.17 million973,000Not Optionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIM ImmunoTech stock logo

AIM ImmunoTech NYSE:AIM

$8.85 -0.32 (-3.49%)
Closing price 07/3/2025 03:30 PM Eastern
Extended Trading
$8.95 +0.10 (+1.13%)
As of 07/3/2025 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

CEL-SCI stock logo

CEL-SCI NYSE:CVM

$2.49 -0.03 (-1.19%)
Closing price 07/3/2025 03:30 PM Eastern
Extended Trading
$2.48 -0.01 (-0.24%)
As of 07/3/2025 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Omega Therapeutics stock logo

Omega Therapeutics NASDAQ:OMGA

$0.12 -0.03 (-21.83%)
Closing price 02/24/2025
Extended Trading
$0.12 0.00 (0.00%)
As of 02/24/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

TradeUP Acquisition stock logo

TradeUP Acquisition NASDAQ:UPTD

TradeUP Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.